|
|
|
LifeScienceHistory.com - Check us out on Instagram
Massachusetts Life Science Industry Directory
Banner Advertising
Please note that we have a new site: LifeScienceHistory.com, "Where history is made daily" under development and
delayed by COVID-19, to be launched in 2023 replacing MassachusettsLifeScience.com. Regrettably, we are working with reduced
staffing and the current industry directory is no longer being maintained, but will be replaced with a new and improved
directory upon the launch of the new site. We apologize for the inconvenience.
Inotek Pharmaceuticals Corporation
| | | Phone: | (781) 676-2100 | Fax: | (781) 676-2155 | Year Established: | 1996 | Ticker: | ITEK | Exchange: | NASDAQ | Main Contact: | David P. Southwell, President & CEO | | Company Description | Inotek is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of therapies for ocular diseases, including glaucoma.
On Oct. 12, 2017, Inotek and Rocket Pharmaceuticals, a leading US-based multi-platform gene therapy company announced a merger agreement . Rocket will receive shares of newly issued Inotek common shares in a private placement. Rocket shareholders are expected to own approximately 81% of the combined Company and current Inotek shareholders will own approximately 19% of the combined Company. | |
|
|
|
|
|